BAY-876, with the CAS number 1799753-63-1, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its role as a selective modulator of the peroxisome proliferator-activated receptor gamma (PPARγ). This compound is characterized by its potential therapeutic applications in metabolic disorders, including type 2 diabetes and obesity, due to its ability to improve insulin sensitivity and regulate glucose metabolism. BAY-876 exhibits a unique chemical structure that contributes to its selectivity and efficacy, distinguishing it from other PPARγ modulators. Additionally, it has been studied for its pharmacokinetic properties, which include absorption, distribution, metabolism, and excretion, essential for determining its suitability for clinical use. As research continues, BAY-876 may provide insights into the development of new treatments for metabolic diseases, emphasizing the importance of understanding its biochemical interactions and effects on cellular pathways.

BAY-876

1799753-63-1: BAY-876, with the CAS number 1799753-63-1, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its role as a selective modulator of the peroxisome proliferator-activated receptor gamma (PPARγ). This compound is characterized by its potential therapeutic applications in metabolic disorders, including type 2 diabetes and obesity, due to its ability to improve insulin sensitivity and regulate glucose metabolism. BAY-876 exhibits a unique chemical structure that contributes to its selectivity and efficacy, distinguishing it from other PPARγ modulators. Additionally, it has been studied for its pharmacokinetic properties, which include absorption, distribution, metabolism, and excretion, essential for determining its suitability for clinical use. As research continues, BAY-876 may provide insights into the development of new treatments for metabolic diseases, emphasizing the importance of understanding its biochemical interactions and effects on cellular pathways.

BAY-876 is a small-molecule inhibitor, which is a synthesized compound with a specific mode of action targeting the glucose transporter 1 (GLUT1). GLUT1 is primarily responsible for glucose uptake across the plasma membranes of mammalian cells, a critical process for cellular metabolism and energy production. BAY-876 inhibits GLUT1 by binding to its active site, thus preventing glucose transport into cells. This inhibition disrupts the metabolic processes within cancer cells, as they heavily rely on glucose for growth and proliferation due to the Warburg effect.

CAS 1799753-63-1

BAY-876

BAY-876

Ref: 3D-ZWC75363